Table II.
Study characteristics for patients receiving chemotherapy for neo-adjuvant cancer.
| Authors (Ref.) | Sample | Mean age (year) | Clinical stage | Mean tumor size (cm) | Drugs and dose | Surgery rate | Outcomes | Toxicities of grade III–IV |
|---|---|---|---|---|---|---|---|---|
| Sirohi, et al 1 (9) | TN: 17 Non-TN: 77 |
TN: 50 Non-TN: 46 |
T3–T4 Nx; M0 |
NR | 5 FU: 200 mg/m2 DDP: 60 mg/m2 EPI: 60 mg/m2 day 1 for 21 days*6 |
6 (35%) P=0.005 54 (70%) P=0.007 |
cCR, PR, pD | NR |
| Chang, et al(10) | TN: 11 Non-TN: 62 |
49.6 | T2–T4 Nx; M0 |
7.75 | DOC: 75 mg/m2 Carboplatin: AUC=6 day 1 for 21 days*4 |
71 | pCR, cCR, 2-year OS, 5-year OS |
Neutropenia, leukopenia, lymphopenia, febrileneutropenia |
| Chen, et al(11) | TN: 24 Non-TN: 84 |
51 | II–IIIC | NR | Carboplatin: AUC=2 Taxol: 180 mg/m2 days 1+8+15 for 28 days*4 |
108 | pCR | Neutropenia, thrombocytopenia, anemia, skin toxicity |
| Silver, et al(6) | TN: 28 | 29–69 | II–III | 3.7 (2.0–7.0) | DDP: 75 mg/m2 day 1 for 21 days*4 |
28 | pCR: 6 (21%) cCR+PR: 18 (64%) PD: 4 (14%) |
Tinnitus, neutropenia, hyperkalemia, elevation of ALT/AST, nausea, myalgia, skin toxicity |
TN, triple-negative breast cancer; Doc, docetaxel; DDP, cisplatin; cCR, clinical complete response; pCR, pathological complete response; PD, progressive disease; OS, overall survival; PFS, progression - free survival; TTP, time to progression; Nx, status of lymph node metastasis is unclear; NR, not reported in the text.